SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-030000
Filing Date
2023-02-09
Accepted
2023-02-09 16:06:01
Documents
12
Period of Report
2023-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

Document Format Files

Seq Description Document Type Size
1 8-K d448723d8k.htm   iXBRL 8-K 24297
  Complete submission text file 0001193125-23-030000.txt   149516

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mtcr-20230203.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mtcr-20230203_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mtcr-20230203_pre.xml EX-101.PRE 11703
6 EXTRACTED XBRL INSTANCE DOCUMENT d448723d8k_htm.xml XML 3513
Mailing Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037
Business Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037 858-369-7800
Metacrine, Inc. (Filer) CIK: 0001634379 (see all company filings)

IRS No.: 472297384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39512 | Film No.: 23606218
SIC: 2834 Pharmaceutical Preparations